Aardvark Therapeutics, Inc. (AARD)
NASDAQ: AARD · Real-Time Price · USD
16.26
-0.33 (-1.99%)
At close: Oct 10, 2025, 4:00 PM EDT
16.00
-0.26 (-1.60%)
After-hours: Oct 10, 2025, 5:13 PM EDT
Aardvark Therapeutics Employees
Aardvark Therapeutics had 22 employees as of December 31, 2024.
Employees
22
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,665,364
Market Cap
352.79M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 22 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AARD News
- 4 days ago - Aardvark Therapeutics Announces FDA Alignment on Protocol Amendment Expanding Phase 3 HERO Trial Population for Prader-Willi Syndrome - GlobeNewsWire
- 18 days ago - Aardvark Therapeutics to Present at the Stifel 2025 Virtual Cardiometabolic Forum - GlobeNewsWire
- 5 weeks ago - Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - GlobeNewsWire
- 5 weeks ago - Aardvark Therapeutics, Inc. (AARD) Presents At Cantor Fitzgerald Global Healthcare Conference 2025 Transcript - Seeking Alpha
- 6 weeks ago - Aardvark Therapeutics to Present at Upcoming Investor Conferences in September - GlobeNewsWire
- 2 months ago - Aardvark Therapeutics Reports Second Quarter 2025 Financial Results and Provides Pipeline and Business Updates - GlobeNewsWire
- 2 months ago - Aardvark Therapeutics Announces ARD-201 Preclinical Obesity Data Showing Significant Weight Loss as a Monotherapy, Enhancement of GLP-1RA Therapy in Combination, and Effective Maintenance Following Discontinuation of GLP-1RA Therapy - GlobeNewsWire
- 3 months ago - Aardvark Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4) - GlobeNewsWire